- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Ceritinib is a novel triple negative breast cancer therapeutic agent ; volume:21 ; number:1 ; day:29 ; month:6 ; year:2022 ; pages:1-16 ; date:12.2022
Molecular cancer ; 21, Heft 1 (29.6.2022), 1-16, 12.2022
- Creator
-
Dong, Shengli
Yousefi, Hassan
Savage, Isabella Van
Okpechi, Samuel C.
Wright, Maryl K.
Matossian, Margarite D.
Collins-Burow, Bridgette M.
Burow, Matthew E.
Alahari, Suresh K.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-022-01601-0
- URN
-
urn:nbn:de:101:1-2022082020181094736849
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dong, Shengli
- Yousefi, Hassan
- Savage, Isabella Van
- Okpechi, Samuel C.
- Wright, Maryl K.
- Matossian, Margarite D.
- Collins-Burow, Bridgette M.
- Burow, Matthew E.
- Alahari, Suresh K.
- SpringerLink (Online service)
Other Objects (12)
Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment
Therapeutic landscape in mutational triple negative breast cancer
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Recent advances in therapeutic strategies for triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Comparative study of triple-negative breast cancer lines to selected therapeutic treatments
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer
Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer
EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment
Therapeutic landscape in mutational triple negative breast cancer
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Recent advances in therapeutic strategies for triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Comparative study of triple-negative breast cancer lines to selected therapeutic treatments
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer
Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer
EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment
Therapeutic landscape in mutational triple negative breast cancer
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Recent advances in therapeutic strategies for triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Comparative study of triple-negative breast cancer lines to selected therapeutic treatments
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer
Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer